Description: Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. It offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to dosage forms for the pharma and consumer health, and nutrition industries, as well as develops cell and gene therapies. The company also provides drinking water sanitizers, nutraceuticals, antidandruff agents, and other personal care ingredients; and agricultural products and advanced coatings and composites, as well as microbial control solutions that combat dangerous viruses, bacteria, and other pathogens. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Home Page: www.lonza.com
Muenchensteinerstrasse 38
Basel,
4002
Switzerland
Phone:
41 61 316 81 11
Officers
| Name | Title |
|---|---|
| Dr. Pierre-Alain Ruffieux Ph.D. | Chief Exec. Officer |
| Mr. Philippe Deecke | Chief Financial Officer |
| Ms. Maria Soler Nunez | Head of Group Operations |
| Mr. Dirk Oehlers | VP of Investor Relations |
| Mr. Andreas Bohrer | Group Gen. Counsel & Company Sec. |
| Ms. Victoria Morgan | Head of External Communications |
| Ms. Jennifer Clancy | Sr. Director of Global Marketing |
| Dr. Caroline Barth M.D. | Chief HR Officer |
| Ms. Constance Ward | Head of External Communications |
| Dr. Sanna Fowler | Head of External Communications |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 26.3158 |
|---|---|
| Trailing PE: | 38.0662 |
| Price-to-Book MRQ: | 3.3755 |
| Price-to-Sales TTM: | 6.1944 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 17154 |